Why AstraZeneca plc’s Patent Cliff Presents A Golden Opportunity

Although AstraZeneca plc (LON: AZN) is in the process of losing many of its high-profile patents, I believe this presents the savvy investor with a golden opportunity

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The term ‘value trap’ is often banded about by financial journalists and investors alike. It means a company whose shares appear to offer good value but, for any number of reasons, is fatally flawed and, as such, is not a wise investment.

Indeed, AstraZeneca (LSE: AZN) (NYSE.AZN.US) is often considered a value trap, having an exceptionally low price-to-earnings (P/E) ratio and a relatively high yield. With shares currently priced at 3147p at the time of writing, AstraZeneca yields 5.6% and has a P/E of just 7.8. This compares well to the healthcare sector which has a P/E of 15.8 and to the FTSE 100 whose P/E is 12.5.

Doomsayers, however, claim that AstraZeneca is a value trap because it is currently experiencing a patent cliff, where many of its biggest selling and highest profile drugs are coming off patent. This means that generic drugs can be manufactured and prices undercut, equating to huge falls in both revenue and profitability for AstraZeneca.

However, I believe that the present situation presents a golden opportunity for investors.

Since the company replaced its CEO in October 2012 it has stepped-up its acquisition spree, recently purchasing a 100% stake in California-based Pearl Therapeutics. It has also ceased its share buyback programme, announced a partnership deal with Roche and plans to increase research and development spending in future years. It certainly has the financial muscle to do so, with debt levels being manageable (the debt/equity ratio is around 43%) and cash flow being impressive too.

Furthermore, dividends per share remain well covered and it is unlikely that they will have to be cut should forecasts prove to be correct and earnings fall over the next few years. However, with a new CEO, the financial clout to pursue an aggressive acquisition strategy, sector-leading R&D facilities as well as partnerships offering significant potential, AstraZeneca’s patent cliff may be somewhat offset by gains made elsewhere.

In that case, a P/E ratio of 7.8 suddenly looks good value, rather than a value-trap, and presents investors with a golden opportunity to buy a high-yielding healthcare company on the cheap.

I own shares in AstraZeneca and would recommend that if you are looking for more opportunities in the FTSE 100, this exclusive wealth report reviews five particularly attractive possibilities.

All five blue chips offer a mix of robust prospects, illustrious histories and dependable dividends, and have just been declared by The Motley Fool as “5 Shares You Can Retire On“.

Simply click here for the report — it’s completely free!

> Peter owns shares in AstraZeneca.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Here’s one excellent FTSE 100 value stock investors should consider buying

Sumayya Mansoor explains why this packaging giant is currently in value stock territory and should be on investors radars.

Read more »

Close-up of British bank notes
Investing Articles

Here’s how much I’d need to invest in dividend shares for £500 a month in passive income

Our writer explores how much he’d need to invest in FTSE 100 dividend shares to generate an attractive second income…

Read more »

Investing Articles

The Rolls-Royce share price won’t stop rising. Am I missing out by not buying?

It's been an exceptional year for the Rolls-Royce share price and this Fool fears he's been missing out. But is…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Dividend Shares

An 8%+ yield? I need to be careful with this dividend forecast

Jon Smith explains why the dividend forecast for a stock is appealing, but it doesn’t necessarily tell the full story…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

2 UK gold stocks I’d buy as bullion prices hit new record highs!

These gold stocks are soaring as prices of the precious metal take off again. Here's why I'd add them to…

Read more »

Investing Articles

These two FTSE 100 stocks are on the rise – is now the time to buy?

As the mining sector enjoys a boost from China, this Fool UK contributor has his eye on two promising FTSE…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

These 2 FTSE 250 shares have been soaring! Should I buy them right now?

These two FTSE 250 shares have posted strong performances in the last year. Here, this Fool explores if now is…

Read more »

Investing Articles

Why the Tesla share price gives the company a huge competitive advantage

The Tesla share price reflects some optimistic assumptions. But Stephen Wright thinks it also gives the company a competitive advantage…

Read more »